Recent Company News

• 08:46 PM ET Feb 11, 2026
  

  NICE recommends Genentech's Gazyvaro with mycophenolate mofetil to treat lupus nephritis (CHF 356.80, 0.00)

• 08:44 AM ET Feb 10, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 04:53 PM ET Feb 09, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:13 PM ET Feb 09, 2026
  

  Follow-up: REGENXBIO announces FDA issues CRL regarding its BLA for RGX-121 (clemidsogene lanparvovec) for the treatment of MPS II ($10.31, 0.00)

• 10:04 PM ET Feb 08, 2026
  

  Nippon Shinyaku reports 9M net income attributable ¥25.84B vs year-ago ¥28.55B (¥5093.0000, +51)

• 01:55 PM ET Jan 30, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 1-Feb

• 07:34 AM ET Jan 28, 2026
  

  REGENXBIO announces FDA places clinical hold on RGX-111 and RGX-121 programs ($13.41, 0.00)

• 10:05 AM ET Jan 26, 2026
  

  Roche Holding's Gazyva approved by Health Canada for use in active lupus nephritis (CHF 349.40, +1.30)

• 09:17 AM ET Jan 20, 2026
  

  Capricor Therapeutics announces FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data to address the CRL ($24.35, 0.00)

• 03:12 PM ET Jan 11, 2026
  

  REGENXBIO issues 2026 catalysts, new Phase I/II RGX-202 functional data demonstrates long-term durable treatment effect at pivotal dose at 18 months ($14.59, 0.00)